A June 2021 review of early RECOVERY results for casirivimab and imdevimab in hospitalised COVID-19 patients. It explains the reported mortality benefit in patients without detectable antibodies, why that finding did not extend to the whole trial population, and the preliminary evidence available then.
REGN monoclonal antibodies work in selected hospitalised COVID-19 patients. St Emlyn’s Read More
A June 2021 look at the first RECOVERY results for aspirin in hospitalised COVID-19 patients. The review considers the absence of a demonstrated mortality benefit, the balance between bleeding and thrombotic events, and the limits of the early results.
JC: Aspirin is not effective for hospitalised COVID19 patients. St Emlyn’s Read More
A March 2021 appraisal of anticoagulation trials in critically ill patients with COVID-19. Simon Carley and Dan Horner examine therapeutic-dose versus usual-care thromboprophylaxis, organ support outcomes and bleeding, explaining why the findings cannot simply be extended to ward patients or treatment of confirmed thrombosis.
JC: Thromboprophylaxis on the ICU for COVID-19 patients. St Emlyn’s Read More
Iain and Simon revisit February 2021 on the St Emlyn’s blog and podcast. The accompanying article links cover TIA risk assessment, proposed emergency care standards, tocilizumab evidence, TXA for epistaxis and conversations with patients about COVID-19 risk.
Podcast – February 2021 Monthly Round Up Read More
A March 2021 review of the RECOVERY convalescent plasma preprint in hospitalised patients with COVID-19. It examines the absence of a survival benefit, donor antibody testing and subgroup findings, and reflects on why promising treatments still need randomised evidence.
JC: Convalescent plasma (still) does not work in COVID-19. St Emlyn’s Read More
A March 2021 update on RECOVERY’s initial colchicine results in hospitalised patients with COVID-19. It reports the lack of a mortality benefit announced at the time, distinguishes these patients from community cases and notes that the full paper was still awaited.
Colchicine does not improve mortality in COVID19. St Emlyn’s Read More
A December 2020 review of RECOVERY’s lopinavir/ritonavir results in hospitalised patients with COVID-19. It discusses the lack of demonstrated benefit, the limits of extrapolating to earlier disease and how adaptive platform trials made rapid evaluation of proposed treatments possible.
JC: Lopinavir/Ritonavir in the treatment of COVID-19 Read More
Thomas Shanahan examines the December 2020 RECOVERY preprint on azithromycin for hospitalised patients with COVID-19. The review covers the absence of a mortality benefit, incomplete follow-up at publication and the importance of avoiding antibiotic use without a supported indication.
JC: Azithromycin in patients hospitalised with COVID-19 Read More
